{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:11:22Z","timestamp":1778908282271,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xkme.2026.101331","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:16:45Z","timestamp":1773422205000},"page":"101331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD 3-5 Stages"],"prefix":"10.1016","volume":"8","author":[{"given":"Wenping","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peitao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhai","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xkme.2026.101331_bib1","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.xkme.2026.101331_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/CIRCULATIONAHA.118.034588","article-title":"Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation via the interplay of OATP2B1 and Dll4-Notch signaling","volume":"139","author":"Nakano","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.xkme.2026.101331_bib3","first-page":"453","article-title":"Guidelines for early screening, diagnosis, prevention and treatment of chronic kidney disease (2022 Edition)","volume":"38","year":"2022","journal-title":"Chin J Nephrol"},{"issue":"12","key":"10.1016\/j.xkme.2026.101331_bib4","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/ndt\/gfl461","article-title":"Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"21","author":"Pisoni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.xkme.2026.101331_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11255-015-1208-5","article-title":"Epidemiology and determinants of pruritus in pre-dialysis chronic kidney disease patients","volume":"48","author":"Solak","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101331_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/toxins11040213","article-title":"The key role of phosphate on vascular calcification","volume":"11","author":"Cozzolino","year":"2019","journal-title":"Toxins (Basel)"},{"issue":"5 suppl 1","key":"10.1016\/j.xkme.2026.101331_bib7","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1053\/j.ajkd.2016.05.024","article-title":"Intensive hemodialysis, mineral and bone disorder, and phosphate binder use","volume":"68","author":"Copland","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.xkme.2026.101331_bib8","first-page":"990","article-title":"Oral phosphate binders in patients with kidney failure","volume":"363","author":"Moe","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000380","article-title":"Chronic kidney disease and the global NCDs agenda","volume":"2","author":"Neuen","year":"2017","journal-title":"BMJ Glob Health"},{"issue":"5","key":"10.1016\/j.xkme.2026.101331_bib10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1053\/j.ajkd.2011.07.020","article-title":"The role of phosphorus in the development and progression of vascular calcification","volume":"58","author":"Kendrick","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.xkme.2026.101331_bib11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","article-title":"Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis","volume":"305","author":"Palmer","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib12","first-page":"154","article-title":"Management of hyperphosphatemia in non-dialysis chronic kidney disease patients","volume":"36","author":"Chen","year":"2020","journal-title":"Chin J Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000358262","article-title":"Dietary acid intake and kidney disease progression in the elderly","volume":"39","author":"Kanda","year":"2014","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101331_bib14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10157-015-1126-y","article-title":"Contemporary management of phosphorus retention in chronic kidney disease: a review","volume":"19","author":"Amiri","year":"2015","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.jrn.2016.08.009","article-title":"Replacing phosphorus-containing food additives with foods without additives reduces phosphatemia in end-stage renal disease patients: a randomized clinical trial","volume":"27","author":"de Fornasari","year":"2017","journal-title":"J Ren Nutr"},{"issue":"1","key":"10.1016\/j.xkme.2026.101331_bib16","first-page":"1","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"issue":"8340","key":"10.1016\/j.xkme.2026.101331_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(83)90014-4","article-title":"Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia","volume":"2","author":"Wills","year":"1983","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.xkme.2026.101331_bib18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007691-199312000-00025","article-title":"Aluminum toxicity in patients with chronic renal failure","volume":"15","author":"Alfrey","year":"1993","journal-title":"Ther Drug Monit"},{"issue":"9","key":"10.1016\/j.xkme.2026.101331_bib19","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.xkme.2026.101331_bib20","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality","volume":"18","author":"London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2026.101331_bib21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2026.101331_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11255-022-03287-1","article-title":"Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric acid secretion inhibitors in patients with chronic kidney disease: a retrospective post hoc analysis","volume":"55","author":"Ito","year":"2023","journal-title":"Int Urol Nephrol"},{"issue":"9900","key":"10.1016\/j.xkme.2026.101331_bib23","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"issue":"pt 1","key":"10.1016\/j.xkme.2026.101331_bib24","article-title":"Alkalihalobacillus clausii PA21 transcriptome profiling and functional analysis revealed the metabolic pathway involved in glycoalkaloids degradation","volume":"242","author":"Song","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2215\/CJN.06800615","article-title":"Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials","volume":"11","author":"Patel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101331_bib26","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.xkme.2026.101331_bib27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101331_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","article-title":"Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials","volume":"68","author":"Palmer","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"7-8","key":"10.1016\/j.xkme.2026.101331_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000531577","article-title":"Comparative efficacy and acceptability of 12 phosphorus-lowering drugs in adults with hyperphosphatemia and chronic kidney disease: a systematic review and network meta-analysis","volume":"52","author":"Luo","year":"2023","journal-title":"Blood Purif"},{"issue":"3","key":"10.1016\/j.xkme.2026.101331_bib30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000168713","article-title":"Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients","volume":"14","author":"Almirall","year":"1994","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2026.101331_bib31","first-page":"423","article-title":"Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients","volume":"60","author":"Caravaca","year":"1992","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1681\/ASN.2008040349","article-title":"Association of serum phosphate with vascular and valvular calcification in moderate CKD","volume":"20","author":"Adeney","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.xkme.2026.101331_bib33","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/14740338.2022.2044472","article-title":"An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles","volume":"21","author":"Ogata","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"15","key":"10.1016\/j.xkme.2026.101331_bib34","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1080\/14656566.2023.2243817","article-title":"Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure","volume":"24","author":"Cernaro","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10.1016\/j.xkme.2026.101331_bib35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2165\/00003088-200241070-00005","article-title":"Sevelamer, a phosphate-binding polymer, is a non-absorbed compound","volume":"41","author":"Plone","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xkme.2026.101331_bib36","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40620-019-00689-w","article-title":"Phosphate binders in chronic kidney disease: an updated narrative review of recent data","volume":"33","author":"Floege","year":"2020","journal-title":"J Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jarr.2003.50016","article-title":"Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients","volume":"10","author":"Burke","year":"2003","journal-title":"Adv Ren Replace Ther"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/17446651.2015.1009368","article-title":"Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis","volume":"10","author":"Locatelli","year":"2015","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.ajkd.2011.12.001","article-title":"Potential interaction between sevelamer and fat-soluble vitamins: a hypothesis","volume":"59","author":"Susantitaphong","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.xkme.2026.101331_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40620-020-00916-9","article-title":"Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study","volume":"34","author":"Molina","year":"2021","journal-title":"J Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2026.101331_bib41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","article-title":"Mortality in kidney disease patients treated with phosphate binders: a randomized study","volume":"7","author":"Di Iorio","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101331_bib42","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101331_bib43","first-page":"345","article-title":"Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease","volume":"18","author":"Mikhail","year":"2017","journal-title":"Nephron Clin Pract"},{"issue":"5 suppl 3","key":"10.1016\/j.xkme.2026.101331_bib44","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2026.101331_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000323095","article-title":"Factors related to the absence of anemia in hemodialysis patients","volume":"32","author":"Verdalles","year":"2011","journal-title":"Blood Purif"},{"issue":"3","key":"10.1016\/j.xkme.2026.101331_bib46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ekir.2016.12.005","article-title":"Ferritin elevation and improved responsiveness to erythropoiesis-stimulating agents in patients on ferric citrate hydrate","volume":"2","author":"Yokoyama","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.xkme.2026.101331_bib47","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gft483","article-title":"A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis","volume":"29","author":"Yokoyama","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.xkme.2026.101331_bib48","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"456","key":"10.1016\/j.xkme.2026.101331_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6474","article-title":"Inhibition of sodium\/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability","volume":"10","author":"King","year":"2018","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.xkme.2026.101331_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MNH.0000000000000236","article-title":"Nicotinamide and phosphate homeostasis in chronic kidney disease","volume":"25","author":"Ginsberg","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"10.1016\/j.xkme.2026.101331_bib51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.xkme.2026.101331_bib52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101331_bib53","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2147\/TCRM.S330649","article-title":"Different effect of lanthanum carbonate and sevelamer hydrochloride on calcium balance in patients with moderate to advanced chronic kidney disease","volume":"17","author":"Makowka","year":"2021","journal-title":"Ther Clin Risk Manag"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:52:18Z","timestamp":1778907138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526000920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2590059526000920"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101331","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD 3-5 Stages","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101331"}}